Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash from Operations: 2012-2024

Historic Cash from Operations for Neurogene (NGNE) over the last 13 years, with Dec 2024 value amounting to -$70.6 million.

  • Neurogene's Cash from Operations fell 25.34% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$77.2 million, marking a year-over-year decrease of 10.30%. This contributed to the annual value of -$70.6 million for FY2024, which is 37.30% down from last year.
  • Latest data reveals that Neurogene reported Cash from Operations of -$70.6 million as of FY2024, which was down 37.30% from -$51.4 million recorded in FY2023.
  • Over the past 5 years, Neurogene's Cash from Operations peaked at -$24.6 million during FY2020, and registered a low of -$70.6 million during FY2024.
  • For the 3-year period, Neurogene's Cash from Operations averaged around -$58.3 million, with its median value being -$52.8 million (2022).
  • As far as peak fluctuations go, Neurogene's Cash from Operations plummeted by 93.52% in 2021, and later climbed by 2.65% in 2023.
  • Yearly analysis of 5 years shows Neurogene's Cash from Operations stood at -$24.6 million in 2020, then plummeted by 93.52% to -$47.6 million in 2021, then declined by 11.07% to -$52.8 million in 2022, then grew by 2.65% to -$51.4 million in 2023, then tumbled by 37.30% to -$70.6 million in 2024.